Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ISPC 
iSpecimen Inc (ISPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ISPC (1-star) is a SELL. SELL since 5 days. Profits (-33.87%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.62% | Avg. Invested days 17 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.91M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.65 | 52 Weeks Range 0.69 - 8.30 | Updated Date 08/29/2025 |
52 Weeks Range 0.69 - 8.30 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate - | Actual -0.42 |
Profitability
Profit Margin -172.51% | Operating Margin (TTM) -255.41% |
Management Effectiveness
Return on Assets (TTM) -76.7% | Return on Equity (TTM) -303.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3687438 | Price to Sales(TTM) 1 |
Enterprise Value 3687438 | Price to Sales(TTM) 1 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA 0.43 | Shares Outstanding 8211160 | Shares Floating 5499628 |
Shares Outstanding 8211160 | Shares Floating 5499628 | ||
Percent Insiders 1.22 | Percent Institutions 1.22 |
Upturn AI SWOT
iSpecimen Inc
Company Overview
History and Background
iSpecimen Inc. was founded in 1999. It provides an online marketplace connecting researchers with human biospecimens, streamlining the process of obtaining samples for research. Over time, it has expanded its network and technology platform to facilitate the procurement of diverse biospecimen types and associated clinical data.
Core Business Areas
- iSpecimen Marketplace: An online platform connecting researchers with biobanks and healthcare organizations to facilitate the procurement of human biospecimens and associated data.
- iSpecimen Solutions: Provides custom biospecimen collection and procurement services, including protocol development, patient recruitment, sample collection, and data management.
Leadership and Structure
Christopher Ianelli, MD, PhD is the CEO. The company has a board of directors and operates with a functional organizational structure encompassing sales, marketing, operations, and technology.
Top Products and Market Share
Key Offerings
- iSpecimen Marketplace: The online marketplace is the primary product, facilitating access to various biospecimen types. Market share is estimated around 25% of the accessible biospecimen marketplace, which is constantly changing with competition arising from traditional biobanks and direct-to-researcher procurement services. Competitors include companies providing bio specimen collection services and biobanks, such as Precision for Medicine and BioIVT.
- iSpecimen Solutions: Custom services for specific research needs. Market share varies depending on the specific research area. Competitors include contract research organizations (CROs) and specialized bio specimen procurement providers.
Market Dynamics
Industry Overview
The biospecimen market is growing due to increased demand for personalized medicine, drug discovery, and diagnostics research. The market is fragmented, with various players including biobanks, CROs, and specialized vendors.
Positioning
iSpecimen Inc. is positioned as a technology-driven facilitator, connecting researchers with bio specimens through its online marketplace and custom solutions. Its competitive advantage lies in its platform's efficiency and breadth of network.
Total Addressable Market (TAM)
The global biospecimen market is estimated at around $50 billion. iSpecimen Inc. is positioned to capture a share of this market by streamlining access to biospecimens and providing custom solutions.
Upturn SWOT Analysis
Strengths
- Extensive network of biobanks and healthcare organizations
- Technology-driven marketplace platform
- Custom biospecimen procurement services
- Focus on quality and compliance
Weaknesses
- Reliance on partner biobanks for specimen quality
- Competition from established biobanks and CROs
- Potential for regulatory changes affecting the biospecimen market
- Limited control over supply chain
- Smaller market share than largest competitors.
Opportunities
- Expansion into new geographic markets
- Development of new biospecimen-related services
- Partnerships with pharmaceutical companies and research institutions
- Leveraging data analytics to improve specimen quality and selection
Threats
- Increased competition from other biospecimen providers
- Changes in regulatory requirements for biospecimen procurement
- Economic downturn affecting research funding
- Data breaches or security vulnerabilities
Competitors and Market Share
Key Competitors
- PPD
- ICON
- Thermo Fisher Scientific (TMO)
Competitive Landscape
iSpecimen Inc.'s advantages lie in its technology platform and extensive network. Disadvantages include competition from larger, more established biobanks and CROs with greater resources.
Growth Trajectory and Initiatives
Historical Growth: iSpecimen Inc. has experienced growth in recent years as the demand for biospecimens has increased.
Future Projections: Future growth is projected to be driven by the increasing demand for personalized medicine and drug discovery.
Recent Initiatives: Recent initiatives include expanding its network of biobanks and healthcare organizations and developing new biospecimen-related services.
Summary
iSpecimen Inc. is a company with moderate market share in a growing but fragmented market. Its marketplace platform offers a valuable service, but it faces competition from larger players. The company's success depends on expanding its network, maintaining specimen quality, and adapting to regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Market research reports
- SEC filings (limited public information available)
- Press releases
- Analyst reports (general industry overview)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may not be precise. Financial data is limited due to lack of readily available sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iSpecimen Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-06-17 | CEO, Treasurer, Secretary & Director Mr. Robert Bradley Lim | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 24 | Website https://ispecimen.com |
Full time employees 24 | Website https://ispecimen.com | ||
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. The company serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.